TY - JOUR
T1 - Management of Stage IIB Cervical Cancer
T2 - an Overview of the Current Evidence
AU - Matsuzaki, Shinya
AU - Klar, Maximilian
AU - Mikami, Mikio
AU - Shimada, Muneaki
AU - Grubbs, Brendan H.
AU - Fujiwara, Keiichi
AU - Roman, Lynda D.
AU - Matsuo, Koji
N1 - Funding Information:
This study is supported by Ensign Endowment for Gynecologic Cancer Research (K.M.).
Funding Information:
Shinya Matsuzaki has received research funding from MSD.
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Purpose of Review: To review and discuss the present evidence of surgery- and radiation-based treatment strategies for stage IIB cervical cancer. Recent Findings: Recently, two randomized controlled trials compared the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy (NACT + RH) with that of concurrent chemoradiotherapy (CCRT) for stage IB3–IIB cervical cancer. When these studies were combined (N = 1259), NACT + RH was associated with a shorter disease-free survival [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.13–1.64], but with a similar overall survival (HR 1.11, 95% CI 0.90–1.36) when compared with the findings for CCRT. Stage-specific analysis for stage IIB cervical cancer demonstrated that disease-free survival was significantly worse with NACT + RH than with CCRT (HR 1.90, 95% CI 1.25–2.89); however, no significant difference was observed for stage IB3–IIA cervical cancer. Summary: Based on the results of recent level I evidence, the standard treatment for stage IIB cervical cancer remains CCRT.
AB - Purpose of Review: To review and discuss the present evidence of surgery- and radiation-based treatment strategies for stage IIB cervical cancer. Recent Findings: Recently, two randomized controlled trials compared the efficacy of neoadjuvant chemotherapy followed by radical hysterectomy (NACT + RH) with that of concurrent chemoradiotherapy (CCRT) for stage IB3–IIB cervical cancer. When these studies were combined (N = 1259), NACT + RH was associated with a shorter disease-free survival [hazard ratio (HR) 1.36, 95% confidence interval (CI) 1.13–1.64], but with a similar overall survival (HR 1.11, 95% CI 0.90–1.36) when compared with the findings for CCRT. Stage-specific analysis for stage IIB cervical cancer demonstrated that disease-free survival was significantly worse with NACT + RH than with CCRT (HR 1.90, 95% CI 1.25–2.89); however, no significant difference was observed for stage IB3–IIA cervical cancer. Summary: Based on the results of recent level I evidence, the standard treatment for stage IIB cervical cancer remains CCRT.
KW - Cervical cancer
KW - Concurrent chemoradiotherapy
KW - Neoadjuvant chemotherapy
KW - Radical hysterectomy
KW - Stage II
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85079339071&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079339071&partnerID=8YFLogxK
U2 - 10.1007/s11912-020-0888-x
DO - 10.1007/s11912-020-0888-x
M3 - Review article
C2 - 32052204
AN - SCOPUS:85079339071
SN - 1523-3790
VL - 22
JO - Current Oncology Reports
JF - Current Oncology Reports
IS - 3
M1 - 28
ER -
